Steven Park

1.1k total citations
29 papers, 518 citations indexed

About

Steven Park is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Steven Park has authored 29 papers receiving a total of 518 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Pathology and Forensic Medicine, 14 papers in Oncology and 11 papers in Genetics. Recurrent topics in Steven Park's work include Lymphoma Diagnosis and Treatment (17 papers), Chronic Lymphocytic Leukemia Research (10 papers) and CAR-T cell therapy research (8 papers). Steven Park is often cited by papers focused on Lymphoma Diagnosis and Treatment (17 papers), Chronic Lymphocytic Leukemia Research (10 papers) and CAR-T cell therapy research (8 papers). Steven Park collaborates with scholars based in United States, Switzerland and Germany. Steven Park's co-authors include Kin Man Au, Andrew Z. Wang, Natalie S. Grover, Oliver W. Press, Christopher Dittus, John P. Leonard, Nancy L. Bartlett, Donald C. Moore, Brandelyn N. Pitcher and Sin‐Ho Jung and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Blood and Clinical Cancer Research.

In The Last Decade

Steven Park

27 papers receiving 516 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Steven Park United States 14 282 227 132 132 121 29 518
Marion Alcantara France 9 259 0.9× 145 0.6× 103 0.8× 121 0.9× 74 0.6× 24 402
Zhengzi Qian China 10 179 0.6× 197 0.9× 120 0.9× 99 0.8× 89 0.7× 29 415
Hoiseon Jeong South Korea 11 295 1.0× 98 0.4× 192 1.5× 115 0.9× 34 0.3× 24 552
Lucy Gong United States 11 294 1.0× 139 0.6× 210 1.6× 134 1.0× 148 1.2× 16 608
Karin Havenith United States 12 679 2.4× 408 1.8× 122 0.9× 173 1.3× 123 1.0× 40 829
Larissa Sandalic United States 9 167 0.6× 63 0.3× 122 0.9× 33 0.3× 111 0.9× 13 403
Patrick H. van Berkel United Kingdom 9 393 1.4× 113 0.5× 112 0.8× 96 0.7× 40 0.3× 35 496
Lida Pacaud United States 12 520 1.8× 66 0.3× 245 1.9× 84 0.6× 51 0.4× 56 621
Elena Ciabatti Italy 12 108 0.4× 103 0.5× 98 0.7× 59 0.4× 148 1.2× 39 437
Eman L. Dadashian United States 7 304 1.1× 111 0.5× 237 1.8× 119 0.9× 135 1.1× 8 536

Countries citing papers authored by Steven Park

Since Specialization
Citations

This map shows the geographic impact of Steven Park's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steven Park with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steven Park more than expected).

Fields of papers citing papers by Steven Park

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Steven Park. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steven Park. The network helps show where Steven Park may publish in the future.

Co-authorship network of co-authors of Steven Park

This figure shows the co-authorship network connecting the top 25 collaborators of Steven Park. A scholar is included among the top collaborators of Steven Park based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Steven Park. Steven Park is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Mani, Rajeswaran, M. Templeton, Lawrence J. Druhan, et al.. (2025). TP53 upregulation via aurora kinase inhibition overcomes primary failure to venetoclax in BCL2-rearranged lymphomas. iScience. 28(6). 112584–112584.
2.
Vaidya, Rakhee, Hamid Ehsan, Tamara K. Moyo, et al.. (2024). Real-World Analysis of Barriers to Timely Administration of Chimeric Antigen Receptor T Cell (CAR T) Therapy in Diffuse Large B-cell Lymphoma. Transplantation and Cellular Therapy. 30(11). 1082.e1–1082.e10. 4 indexed citations
3.
Ghosh, Nilanjan, Danielle Boselli, Bei Hu, et al.. (2024). Evaluation of the Impact of Monitoring for Tumor Lysis During Venetoclax Ramp-Up in Chronic Lymphocytic Leukemia in Routine Clinical Practice. JCO Oncology Practice. 21(5). 677–682. 1 indexed citations
4.
5.
Ehsan, Hamid, Tamara K. Moyo, Bei Hu, et al.. (2023). Real-World Analysis of Barriers to Timely Administration of Chimeric Antigen Receptor T-Cell (CART) Therapy in Diffuse Large B-Cell Lymphoma (DLBCL). Blood. 142(Supplement 1). 7393–7393. 3 indexed citations
6.
Hamadeh, Issam S., Jai N. Patel, Ryan Jacobs, et al.. (2023). Genetic Predictors of Ibrutinib-related Cardiovascular Side Effects in Patients with Chronic Lymphocytic Leukemia. Clinical Cancer Research. 29(23). 4941–4948. 4 indexed citations
7.
Foureau, David, Fei Guo, Nury Steuerwald, et al.. (2023). Prognostic significance of myeloid-derived suppressor cells and systemic inflammation in newly diagnosed diffuse large B cell lymphoma treated with chemoimmunotherapy. Experimental Hematology. 129. 104125–104125. 1 indexed citations
8.
Au, Kin Man, Steven Park, & Andrew Z. Wang. (2020). Trispecific natural killer cell nanoengagers for targeted chemoimmunotherapy. Science Advances. 6(27). eaba8564–eaba8564. 89 indexed citations
9.
Au, Kin Man, Andrew Z. Wang, & Steven Park. (2020). Pretargeted delivery of PI3K/mTOR small-molecule inhibitor–loaded nanoparticles for treatment of non-Hodgkin’s lymphoma. Science Advances. 6(14). eaaz9798–eaaz9798. 45 indexed citations
10.
Park, Hoon, et al.. (2020). The Compositional and Functional Properties of Kombucha: A Literature Review. Food Engineering Progress. 24(1). 1–14. 5 indexed citations
11.
Park, Steven, Steven P. Angus, Dirk P. Dittmer, et al.. (2019). Inhibition of Aurora A Kinase in Combination with Chemotherapy Induces Synthetic Lethality and Overcomes Chemoresistance in Myc-Overexpressing Lymphoma. Targeted Oncology. 14(5). 563–575. 14 indexed citations
12.
Wong, Jason P., Timothy J. Stuhlmiller, Louise Giffin, et al.. (2019). Kinome profiling of non-Hodgkin lymphoma identifies Tyro3 as a therapeutic target in primary effusion lymphoma. Proceedings of the National Academy of Sciences. 116(33). 16541–16550. 15 indexed citations
13.
Persky, Daniel O., Hongli Li, Deborah M. Stephens, et al.. (2019). PET-Directed Therapy for Patients with Limited-Stage Diffuse Large B-Cell Lymphoma - Results of Intergroup Nctn Study S1001. Blood. 134(Supplement_1). 349–349. 8 indexed citations
14.
Moore, Donald C., et al.. (2019). Mogamulizumab: An Anti-CC Chemokine Receptor 4 Antibody for T-Cell Lymphomas. Annals of Pharmacotherapy. 54(4). 371–379. 33 indexed citations
15.
Hu, Bei, Danielle Boselli, James T. Symanowski, et al.. (2019). Minorities Do Not Have Worse Outcomes for Diffuse Large B Cell Lymphoma (DLBCL) If Optimally Managed. Blood. 134(Supplement_1). 425–425. 2 indexed citations
16.
17.
Smith, Sonali M., Brandelyn N. Pitcher, Sin‐Ho Jung, et al.. (2017). Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials. The Lancet Haematology. 4(4). e176–e182. 63 indexed citations
18.
Eason, Anthony B., Sang‐Hoon Sin, Blossom Damania, et al.. (2016). Differential IgM expression distinguishes two types of pediatric Burkitt lymphoma in mouse and human. Oncotarget. 7(39). 63504–63513. 4 indexed citations
19.
Park, Steven, Donald K. Hamlin, Yukang Lin, et al.. (2011). Pretargeted Radioimmunotherapy Using Genetically Engineered Antibody-Streptavidin Fusion Proteins for Treatment of Non-Hodgkin Lymphoma. Clinical Cancer Research. 17(23). 7373–7382. 27 indexed citations
20.
Park, Steven & Oliver W. Press. (2007). Radioimmunotherapy for treatment of B-cell lymphomas and other hematologic malignancies. Current Opinion in Hematology. 14(6). 632–638. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Marion Alcantara Breakdown of academic impact, for papers by Zhengzi Qian Breakdown of academic impact, for papers by Hoiseon Jeong Breakdown of academic impact, for papers by Lucy Gong Breakdown of academic impact, for papers by Karin Havenith Breakdown of academic impact, for papers by Larissa Sandalic Breakdown of academic impact, for papers by Patrick H. van Berkel Breakdown of academic impact, for papers by Lida Pacaud Breakdown of academic impact, for papers by Elena Ciabatti Breakdown of academic impact, for papers by Eman L. Dadashian
Rankless by CCL
2026